17 completed, 10 recruiting, 10 terminated, 8 active not recruiting. 59 Phase 1, 20 Phase 2.
Follow Gastric Adenocarcinoma: new trials by email Literature Review of Gastric Adenocarcinoma trials Research Report on Gastric Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ACC-1898 in Adult Participants With Advanced Solid Tumors ACC-1898 - Hepatocellular Carcinoma, Renal Cell Carcinoma | Phase 1 | Not yet recruiting | AccSalus Biosciences, Inc. | 40 | 2027-01-01 | 2026-10-28 |
| Magnetic Sentinel Lymph Node Mapping in Gastric Cancer Gastrectomy, Indocyanine Green, Iron Conjugated Polymers in Saline Suspension - Gastric Adenocarcinoma | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 20 | 2026-12-31 | 2026-08-14 |
| Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma BHB810 - Gastric Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | BigHat Biosciences, Inc. | 164 | 2026-07-16 | 2026-10-20 |
| A Phase 1 Study Evaluating DISP-10 in Participants With Advanced Gastrointestinal Cancers DISP-10 - Colorectal Cancer, Gastric Adenocarcinoma | Phase 1 | Recruiting | Dispatch Biotherapeutics | 66 | 2026-04-13 | 2026-10-05 |
| AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors AVA6103 - Vulvar Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma | Phase 1 | Recruiting | Avacta Life Sciences Ltd | 174 | 2026-03-31 | 2026-10-05 |
| A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors IDE892, IDE397 - NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC) | Phase 1 | Recruiting | IDEAYA Biosciences | 260 | 2026-03-04 | 2026-09-28 |
| Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction and Gastric Cancers Capecitabine, Docetaxel, Fluorouracil - Clinical Stage I Gastric Cancer AJCC v8, Clinical Stage II Gastric Cancer AJCC v8 | Phase 1 | Withdrawn | Ohio State University Comprehensive Cancer Center | 2025-12-31 | 2025-02-07 | |
| A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric Adenocarcinoma Tislelizumab, FLOT Chemotherapy - Esophagogastric Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 18 | 2025-12-12 | 2025-12-19 |
| First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors PLX-61639 - Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma | Phase 1 | Recruiting | Plexium, Inc. | 155 | 2025-12-01 | 2026-06-12 |
| A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors NRM-823 - HNSCC, ESCC | Phase 1 | Recruiting | Normunity AccelCo, Inc. | 150 | 2025-10-30 | 2026-08-18 |
| Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors BL-M05D1 - Gastric Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma | Phase 1 | Active not recruiting | SystImmune Inc. | 160 | 2025-07-30 | 2026-08-05 |
| Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors vvDD-hIL-2-RG-1 - Gastric Neoplasms, Esophageal Cancer | Phase 1 | Recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 18 | 2025-05-06 | 2025-06-03 |
| Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients Drug: CT041 autologous CAR T-cell injection - Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma | Phase 1 | Not yet recruiting | Peking University | 48 | 2025-03-10 | 2025-03-04 |
| Fruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer fruquintinib + tislelizumab + FOLFOX - Gastric (Stomach) Cancer, Gastric Adenocarcinoma | Phase 1 / Phase 2 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 44 | 2025-03-01 | 2025-03-12 |
| A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation PRT7732 - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Terminated | Prelude Therapeutics Incorporated | 42 | 2024-11-04 | 2026-02-02 |
| A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma Drug: AK129 Drug：oxaliplatin Drug：capecitabine, Drug: AK129 Drug: cadonilimab Drug: oxaliplatin Drug: capecitabine - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 1 / Phase 2 | Completed | Akeso | 35 | 2024-09-30 | 2026-10-16 |
| A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors sigvotatug vedotin - Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck | Phase 1 | Completed | Seagen, a wholly owned subsidiary of Pfizer | 6 | 2024-08-21 | 2025-12-15 |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors APL-5125 - Colorectal Cancer, Cholangiocarcinoma | Phase 1 | Completed | Apollo Therapeutics Ltd | 27 | 2024-06-18 | 2026-10-05 |
| Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer fruquintinib＋trastuzumab + XELOX - Gastric Adenocarcinoma, Gastric (Stomach) Cancer | Phase 1 / Phase 2 | Recruiting | Henan Cancer Hospital | 45 | 2024-02-22 | 2026-01-12 |
| A Study of KK2269 in Adult Participants With Solid Tumors KK2269, Docetaxel - Advanced Solid Tumor, Metastatic Solid Tumor | Phase 1 | Active not recruiting | Kyowa Kirin Co., Ltd. | 83 | 2024-01-18 | 2026-10-26 |
Showing 20 of 59. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (16) · Stomach Neoplasms (15) · Adenocarcinoma Of Esophagus (14) · Squamous Cell Carcinoma of Head and Neck (13) · Colorectal Neoplasms (10) · Pancreatic Neoplasms (9) · Carcinoma, Renal Cell (8) · Carcinoma, Transitional Cell (8) · Breast Neoplasms (6) · Carcinoma, Hepatocellular (6) · Esophageal Squamous Cell Carcinoma (6) · Neoplasm Metastasis (6) · Small Cell Lung Carcinoma (6) · Triple Negative Breast Neoplasms (6) · Melanoma (5)
Neoplasms by Site (43) · Neoplasms (40) · Digestive System Diseases (39) · Digestive System Neoplasms (39) · Gastrointestinal Diseases (32) · Neoplasms by Histologic Type (29) · Neoplasms, Glandular and Epithelial (29) · Carcinoma (28) · Gastrointestinal Neoplasms (28) · Respiratory Tract Neoplasms (20) · Thoracic Neoplasms (20) · Head and Neck Neoplasms (19) · Lung Diseases (19) · Respiratory Tract Diseases (19) · Bronchial Neoplasms (18)
pembrolizumab (11) · Oxaliplatin (9) · Fluorouracil (8) · Capecitabine (7) · Leucovorin (6) · Irinotecan (5) · Nivolumab (4) · Ramucirumab (4) · Paclitaxel (3) · dehydroftorafur (3) · Albumin-Bound Paclitaxel (2) · Cisplatin (2) · Docetaxel (2) · Folfox protocol (2) · Radiation (2)
Peking University (4) · Eli Lilly and Company (3) · Akeso (2) · Gilead Sciences (2) · M.D. Anderson Cancer Center (2) · National Cancer Center Hospital East (2) · AccSalus Biosciences, Inc. (1) · Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) (1) · Apollo Therapeutics Ltd (1) · Astellas Pharma Global Development, Inc. (1) · Avacta Life Sciences Ltd (1) · Basilea Pharmaceutica (1) · BigHat Biosciences, Inc. (1) · CARsgen Therapeutics Co., Ltd. (1) · Curegenix Inc. (1)
United States (37) · China (16) · Japan (8) · Spain (6) · Germany (4) · South Korea (4) · Belgium (3) · France (3) · United Kingdom (3) · Australia (2) · Canada (2) · Chile (2) · Italy (2) · Turkey (Türkiye) (2) · Argentina (1)
Kohei Shitara, MD (2) · Afsaneh Barzi, MD (1) · Anish Thomas, MD (1) · Apostolia Tsimberidou, MD, PhD (1) · Brian D Badgwell (1) · Christina Derleth, MD (1) · Cyndi Sirard, MD (1) · David P Ryan, MD (1) · Dayssy A Diaz Pardo, MD, MS (1) · Edward Chan, MD (1) · Farshid Dayyani, MD, PhD (1)
PMID 25915780, PMID 25944802, PMID 26106073, PMID 26541586, PMID 28291390, PMID 28548889, PMID 28558150, PMID 28679770, PMID 29853658, PMID 30786188, PMID 31189049, PMID 31236579, PMID 31301962, PMID 32946924, PMID 33068794, PMID 33492986, PMID 33613701, PMID 33741442, PMID 34606846, PMID 34992093, PMID 35048809, PMID 35623069, PMID 35728046, PMID 35773363, PMID 36569905, PMID 37689733, PMID 38788174, PMID 38809056, PMID 39792482, PMID 40042547, PMID 40210967, PMID 40460847, PMID 40481574, PMID 40657894, PMID 41724817
2015 (1), 2023 (1), P30CA014089 (1), P30CA014599 (1)